The Association of Advanced Regenerative Medicine Industries (CARM, Chairman Lee Deuk-ju) announced that it will hold the 5th Advanced Regenerative Medicine Development Strategy Forum at COEX, Seoul on Wednesday, November 13.
This forum, which celebrates its 5th anniversary this year, will be held within the exhibition hall of KOREA LIFE SCIENCE WEEK 2024, a premium exhibition and conference representing the life science field in Korea.
This forum has the theme of ‘D-100, Implementation of the Amendment to the Advanced Regenerative Bio Act and Next-Generation Technology Innovation Strategy’, and is scheduled to be implemented in February next year as the ‘Act on Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals’ (abbreviated as ‘Advanced Regenerative Biotechnology’). Regarding the amendments to the law, representatives from industry, government, medical institutions, researchers, and patient groups will participate in a panel discussion to represent the positions of each field and explore response plans and strategies. CARM Policy Committee Chairman Chae-ok Yoon (CEO of Jin Medicine) chaired the panel discussion, and Stem and Gene Division Director Mi-hyeon Jeong (CTX Executive Director) gave the presentation.
The main change in the amendment to the Advanced Regenerative Bio Act is that ‘treatment’ with advanced regenerative medicine has become possible, and the scope of clinical research has been expanded from serious, rare, and incurable diseases to all diseases. The main purpose of this is to promote clinical research in the field of advanced regenerative medicine, guarantee the right to treatment for patients with rare and incurable diseases, and contribute to improving public health. This discussion is expected to be a meaningful opportunity to emphasize the importance of close cooperation between researchers, patients, companies, and the government, explore innovative measures incorporating diverse perspectives, and discuss policy support measures.
Other sessions will cover the development of advanced biopharmaceutical evaluation and analysis technologies and the current status of induced pluripotent stem cell treatment development. In the advanced biopharmaceutical evaluation and analysis technology development session, GC Cell Research Center Director Won Seong-yong and Kangstem Biotech Research Center Director Lee Seung-hee served as moderators and discussed ▲future challenges and opportunities for humanized animal models ▲organoid-based evaluation technology in advanced biopharmaceutical research and development. ▲A presentation will be made on holotomography and artificial intelligence-based 3D imaging technology for cells, tissues, and organoids.
The current status of induced pluripotent stem cell treatment development session was chaired by Hwang Yoo-kyung, CEO of CTX, and Lee Shin-jeong, Managing Director of Charis Bio. ▲Development of iPSC culture medium using cell-customized medium development platform technology ▲Case of development of cell therapy based on induced pluripotent stem cells ▲Induced pluripotent stem cell A presentation will be made on considerations for commercial production.
During the KOREA LIFE SCIENCE WEEK 2024 event period (November 12 to November 14), a separate advanced regenerative bio promotion center will be operated within the exhibition hall. The public relations center was designed to support the promotion and business partnering of the technology and products of domestic advanced regenerative bio companies and to publicize the latest trends in the advanced regenerative bio industry. Participating in the promotional center are ▲Plabiologics, ▲HK Innoen, ▲Lucas Bio, ▲Excel Therapeutics, ▲National Institute for Bioethics Policy, and ▲Advanced Regenerative Medicine Industry Association.
Pre-registration for the exhibition and forum is until 5 p.m. on Monday, November 11, and is available on the KOREA LIFE SCIENCE WEEK 2024 website. (
Meanwhile, CARM’s Policy Committee (Chairman, Gene Medicine CEO Yoon Chae-ok) delivered the industry’s opinion to the Ministry of Health and Welfare in relation to this year’s amendment to the Advanced Regenerative Bio Act and the revision of subordinate laws, and the Association has made various efforts to develop the advanced regenerative bio industry and create an ecosystem. The business is being actively carried out.
Send article to Facebook
Send article to Twitter
Send article to Kakao Story
Send article to Copy URL
close
2024-11-09 12:26:00